Marengo begins patient dosing in STARt─002 phase 1b/2 study of invikafusp alfa in combo with TROP2─directed ADC Trodelvy ...
Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneering novel approaches to precision T cell activation, announced that the first patient has been dosed in its STARt-002 clinical trial. The phase 1b/2 study evaluates the safety …